Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference
Nyxoah, a medical technology company based in Belgium, has announced its participation in the Canaccord Genuity 42nd Annual Growth Conference in Boston from August 8 to 11, 2022. Olivier Taelman, CEO, will present a corporate update on August 10 at 3:30pm EDT. Investors can access the live webcast on the Company's Investor Relations website. Nyxoah specializes in solutions for Obstructive Sleep Apnea (OSA) and features the Genio® system, an innovative therapy recognized with a CE Mark since 2019.
- None.
- None.
Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference
Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the Canaccord Genuity 42nd Annual Growth Conference, which will take place in Boston, Massachusetts, from August 8 to 11, 2022.
Olivier Taelman, Nyxoah’s Chief Executive Officer, is scheduled to present a corporate update on Wednesday, August 10, 2022, at 3:30pm EDT. A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1x1 meetings with institutional investors attending the event.
Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494
Attachment
FAQ
What is the date and time of Nyxoah's presentation at the Canaccord Genuity Conference?
Where will the Canaccord Genuity 42nd Annual Growth Conference take place?
What is the focus of Nyxoah's presentation at the conference?
What innovative product does Nyxoah offer for Obstructive Sleep Apnea?
What regulatory approval did Nyxoah receive for the Genio® system?
Is Nyxoah publicly traded, and if so, what is its stock symbol?
